Wixela Inhub Dosage
Generic name: FLUTICASONE PROPIONATE 100ug, SALMETEROL XINAFOATE 50ug
Dosage form: inhalation powder
Medically reviewed by Drugs.com. Last updated on Jan 8, 2019.
Wixela™ Inhub™ should be administered as 1 inhalation twice daily by the orally inhaled route only. After inhalation, the patient should rinse his/her mouth with water without swallowing to help reduce the risk of oropharyngeal candidiasis.
More frequent administration or a greater number of inhalations (more than 1 inhalation twice daily) of the prescribed strength of Wixela™ Inhub™ is not recommended as some patients are more likely to experience adverse effects with higher doses of salmeterol. Patients using Wixela™ Inhub™ should not use additional LABA for any reason. [See Warnings and Precautions (5.3, 5.12).]
If asthma symptoms arise in the period between doses, an inhaled, short-acting beta2-agonist should be taken for immediate relief.
Adult and Adolescent Patients Aged 12 Years and Older
For patients aged 12 years and older, the dosage is 1 inhalation twice daily, approximately 12 hours apart.
When choosing the starting dosage strength of Wixela™ Inhub™, consider the patients’ disease severity, based on their previous asthma therapy, including the ICS dosage, as well as the patients’ current control of asthma symptoms and risk of future exacerbation.
The maximum recommended dosage is Wixela™ Inhub™ 500/50 twice daily.
Improvement in asthma control following inhaled administration of Wixela™ Inhub™ can occur within 30 minutes of beginning treatment, although maximum benefit may not be achieved for 1 week or longer after starting treatment. Individual patients will experience a variable time to onset and degree of symptom relief.
For patients who do not respond adequately to the starting dosage after 2 weeks of therapy, replacing the current strength of Wixela™ Inhub™ with a higher strength may provide additional improvement in asthma control.
If a previously effective dosage regimen fails to provide adequate improvement in asthma control, the therapeutic regimen should be reevaluated and additional therapeutic options (e.g., replacing the current strength of Wixela™ Inhub™ with a higher strength, adding additional ICS, initiating oral corticosteroids) should be considered.
Chronic Obstructive Pulmonary Disease
The recommended dosage for patients with COPD is 1 inhalation of Wixela™ Inhub™ 250/50 twice daily, approximately 12 hours apart.
If shortness of breath occurs in the period between doses, an inhaled, short-acting beta2-agonist should be taken for immediate relief.
More about Wixela Inhub (fluticasone / salmeterol)
- Side Effects
- During Pregnancy
- Drug Interactions
- Pricing & Coupons
- 9 Reviews
- Drug class: bronchodilator combinations
- FDA Alerts (3)
- FDA Approval History